PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) Net Income (Continuing Operations) : Rp1,040,862 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is PT Industri Jamu dan Farmasi Sido Muncul Tbk Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. PT Industri Jamu dan Farmasi Sido Muncul Tbk's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was Rp390,493 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was Rp1,040,862 Mil.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Net Income (Continuing Operations) Historical Data

The historical data trend for PT Industri Jamu dan Farmasi Sido Muncul Tbk's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Net Income (Continuing Operations) Chart

PT Industri Jamu dan Farmasi Sido Muncul Tbk Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

807,689.00

934,016.00

1,260,898.00

1,104,714.00

950,648.00

PT Industri Jamu dan Farmasi Sido Muncul Tbk Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															300,279.00	147,828.00	138,466.00	364,075.00	390,493.00

PT Industri Jamu dan Farmasi Sido Muncul Tbk Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp1,040,862 Mil.

PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of PT Industri Jamu dan Farmasi Sido Muncul Tbk's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jalan Gajahmada No. 123, 1st Floor, Gedung Hotel Tentrem, Office Sido Muncul, Lantai 1, Semarang, IDN, 50134

Website

https://www.sidomuncul.co.id

PT Industri Jamu dan Farmasi Sido Muncul Tbk is biotechnology company that provides herbal medicine and pharmaceutical products. The company has three business segments, Herbal Medicine, Food and Beverage, and Pharmacy. The Herbal Medicine segment provides herbal supplements, while its Food and Beverage segment sells packaged foods, soft drinks, and candy and confectionary products. The Pharmacy segment sells pharmaceutical products such as Anacetine, a fever reducer, Berlosid, a medicine to reduce gastric pain, and Combicitrine, a medicine for bacterial removal. The company generates the majority of its revenue in Indonesia.

PT Industri Jamu dan Farmasi Sido Muncul Tbk (ISX:SIDO) Headlines

No Headlines